Andrew Mulberg, MD

Dr. Mulberg is an executive pharmaceutical leader with extensive expertise in the strategic and operational aspects of drug and biologic development for NDA and BLA submissions for pediatric and adult rare diseases, cystic fibrosis, gastroenterology and hepatology. He is currently Senior Vice-President, Regulatory Affairs, Quality Assurance and Quality Control at Neurogene Inc, a company devoted to the development of gene therapy approaches for the management of neurodegenerative and neurodevelopmental disorders in children and adults. He previously served as Senior Vice-President, Global Regulatory Affairs, at Amicus Therapeutics, as Division Deputy Director of Gastroenterology and Inborn Errors Products, CDER, FDA, and as Portfolio Leader, Internal Medicine, Established products, at Johnson & Johnson. Dr. Mulberg is a graduate of Columbia College of Columbia University and of the Mount Sinai School of Medicine. He completed his residency in Pediatrics at the Children’s Hospital of Philadelphia as well as a pediatric gastroenterology clinical fellowship and a post-doctoral fellowship in cellular and molecular physiology at the New England Medical Center. Dr. Mulber is Adjunct Professor of pediatrics at University of Maryland School of Medicine and has served as Attending, pediatric gastroenterology and nutrition, at Cooper University Hospital in New Jersey, caring for children with gastrointestinal diseases.